$740,000.00 in Sales Expected for XOMA Corp (NASDAQ:XOMA) This Quarter

Share on StockTwits

Equities analysts expect that XOMA Corp (NASDAQ:XOMA) will post $740,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for XOMA’s earnings. The highest sales estimate is $1.22 million and the lowest is $260,000.00. XOMA posted sales of $900,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 17.8%. The company is expected to issue its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that XOMA will report full-year sales of $10.59 million for the current financial year, with estimates ranging from $9.68 million to $11.50 million. For the next year, analysts expect that the business will post sales of $5.20 million, with estimates ranging from $1.80 million to $8.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for XOMA.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. The business had revenue of $0.96 million during the quarter, compared to analyst estimates of $0.63 million. XOMA had a negative net margin of 72.20% and a negative return on equity of 51.91%.

A number of analysts have recently issued reports on the stock. HC Wainwright set a $30.00 price target on shares of XOMA and gave the company a “buy” rating in a report on Friday, June 14th. ValuEngine downgraded shares of XOMA from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Finally, Wedbush reaffirmed a “buy” rating and set a $25.00 price target on shares of XOMA in a report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. XOMA has a consensus rating of “Hold” and a consensus price target of $27.50.

Shares of NASDAQ XOMA traded down $0.22 during trading on Friday, reaching $16.47. 51,996 shares of the company traded hands, compared to its average volume of 63,860. The firm’s 50 day moving average price is $17.10. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.90 and a quick ratio of 3.90. The stock has a market capitalization of $151.29 million, a PE ratio of -10.36 and a beta of 1.29. XOMA has a 52-week low of $11.02 and a 52-week high of $20.29.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Smart Portfolios LLC bought a new stake in XOMA in the first quarter worth $36,000. Athanor Capital LP purchased a new position in XOMA during the second quarter worth $149,000. California Public Employees Retirement System boosted its stake in XOMA by 11.5% during the fourth quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,220 shares during the period. First Manhattan Co. boosted its stake in XOMA by 100.0% during the first quarter. First Manhattan Co. now owns 20,000 shares of the biotechnology company’s stock worth $247,000 after buying an additional 10,000 shares during the period. Finally, Morgan Stanley boosted its stake in XOMA by 2,151.6% during the second quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after buying an additional 22,828 shares during the period. 47.63% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

See Also: Day Trading

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.